Harvard Bioscience is counting on huge returns from its Asia strategy where it plans to partner with Chinese companies and expand its distribution, says the scientific instrument-seller's CEO Jeff Duchemin. Duchemin says the company has gone through a major transformation after spinning off its regenerative technology unit last year, plus he says the harsh winter hampered sales in the first quarter. He says the company is now moving forward, especially in China, where he says the company is well positioned against traditional competitors like Thermo Fisher as well as smaller ones that continue to pop up.

More from Emerging Markets

Capital Expenditure Growth Could Be a Casualty of Expanded Trade War

Capital Expenditure Growth Could Be a Casualty of Expanded Trade War

3 Big-Name ETFs Being Hurt by U.S. Trade War With China

3 Big-Name ETFs Being Hurt by U.S. Trade War With China

Markets Look Confused After Latest Beating

Markets Look Confused After Latest Beating

China Central Bank Governor Says Stay 'Calm and Rational' After Market Free Fall

China Central Bank Governor Says Stay 'Calm and Rational' After Market Free Fall

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats